Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

Zepbound is a medicine you can obtain only by prescription, and it's typically used to address obesity and other ...

Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls in sales could portend weaker long-term potential for this market. Lilly is positioned to remain the ...

Weight-loss drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound are generating billions of dollars in sales Pharma rival Novo Nordisk (NYSE:NVO) was the first to market with its GLP-1 ...

are used in diabetes and obesity drugs like Eli Lilly's Mounjaro and Zepbound. The stock (LLY) dropped 8.2% in morning trading, enough to make it the S&P 500 index's SPX worst performer.

Eli Lilly & Co.'s Zepbound ... look at waist-to-height ratio (an assessment of body fat distribution, which is linked to heart disease risk)? Or should they aim for specific health markers, like ...

"FDA is aware that some patients and health care professionals may look to unapproved versions ... windy day': Live updates GLP-1 class drugs like Zepbound and Mounjaro form part of a larger ...

Zepbound's sales were already growing fast ... had predicted a 25% mean weight loss for CagriSema, but it still looks like the company has a better product on its hands. CagriSema is just one ...